Our
Product Pipeline
We take a scientifically driven approach to designing our ProTides, which have the potential to result in highly efficacious cancer therapies with improved tolerability.
Our pipeline of clinical product candidates is summarized below:
Applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines .
Our
ProTide Candidates
Learn more about our leading ProTide candidates and our clinical studies
NUC-3373 Studies
NUC-3373 is being investigated in two clinical studies including a Phase 1b/2 study in patients with advanced colorectal cancer.
NUC-7738 Studies
NUC-7738 is being investigated in a Phase 1/2 study for patients with advanced solid tumors.
